MONT-SAINT-GUIBERT, Belgium, March 23, 2017 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD), a leader in the discovery and development of engineered cell therapies, with clinical programs in immuno-oncology, today provides an update on its recent operations and reported consolidated financial results for the twelve-month period ended 31 December 2016, prepared in accordance with IFRS.
Commenting on the 2016 results, Christian Homsy, CEO of Celyad, said: “2016 has been a challenging year in which our CAR-T portfolio has continued to develop, with the company building its expertise in the field of immuno-oncology, and one in which we transitioned from a focus on cardiology to being one of the most promising prospects in the field of next generation CAR-T cells.”
Conference Call Details
A conference call will be held on Thursday, 23 March 2017 at 2:00 p.m. CET / 8:00am EST to review the financial results. Christian Homsy, Chief Executive Officer, and Patrick Jeanmart, Chief Financial Officer will deliver a brief presentation followed by a Q&A session.
SharePrint
March 23, 2017 02:00 ET | Source: Celyad SA
First clinical trial of CAR-T NKR-2 cell therapy completed with encouraging safety profile and unexpected signals of clinical activity at the low doses tested.
Strong cash position expected to fund operations until mid-2019.
Key 2016 Highlights
Completion of first CAR-T NKR-2 Phase I trial, confirming safety of CAR-T NKR-2 cells but also reporting unexpected clinical activity in patients suffering from AML and MM.
Signature of strategic collaboration agreements with ONO Pharmaceuticals and Institut Curie to support development of immuno-oncology programs.
Approval from Belgian regulatory authorities to start THINK Phase I trial in Belgium. Release of CHART-1 data 9-month primary endpoint. Results for the CHART-1 European Phase III clinical trial evaluating C-Cure® cell therapy did not meet the primary endpoint Strong cash position: EUR 82.6 million as of 31 December 2016. Expected 2017 Milestones
Initiation of THINK trial (USA) in Q1 2017.
Initiation of SHRINK study (US/EU) in Q2 2017.
Initiation of LINK study (EU) in Q3 2017.
THINK dose-escalation results expected in Q4 2017.
MONT-SAINT-GUIBERT, Belgium, March 23, 2017 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD), a leader in the discovery and development of engineered cell therapies, with clinical programs in immuno-oncology, today provides an update on its recent operations and reported consolidated financial results for the twelve-month period ended 31 December 2016, prepared in accordance with IFRS.
Commenting on the 2016 results, Christian Homsy, CEO of Celyad, said: “2016 has been a challenging year in which our CAR-T portfolio has continued to develop, with the company building its expertise in the field of immuno-oncology, and one in which we transitioned from a focus on cardiology to being one of the most promising prospects in the field of next generation CAR-T cells.”
Conference Call Details
A conference call will be held on Thursday, 23 March 2017 at 2:00 p.m. CET / 8:00am EST to review the financial results. Christian Homsy, Chief Executive Officer, and Patrick Jeanmart, Chief Financial Officer will deliver a brief presentation followed by a Q&A session.
Joining the Conference Call:
1. In the 10 minutes prior to the call start time, call the appropriate participant dial-in number.
Standard International Dial-In Number: +44 (0) 1452 560304
Local Call Dial-In Numbers:
• Belgium 024017052
• France 0170700785
• UK 08448719299
• Netherlands 0207133453 • US 16316215256
2. Provide the operator with the conference ID 87117681
Helpful keypad commands: *0 - Operator assistance.
